News and media

AACMC Meeting 11 discusses medicinal cannabis regulation, implementation of the McMillan Review, industry challenges and patient access pathways.

AACMC Meeting 10 highlights medicinal cannabis regulatory updates, growing SAS approvals, industry compliance measures and review of the Narcotic Drugs Act.

The Office of Drug Control is implementing the 26 recommendations from the Report on the Review of the Narcotic Drugs Act 1967.

Report on the Review into the 2016 medicinal cannabis amendments to the Narcotic Drugs Act 1967 was tabled in Parliament on Thursday 5 September 2019.

The Australian Government will boost the nation's medicinal cannabis industry by prioritising projects that have been granted Major Project Status (MPS) and ultimately driving economic growth.

AACMC Meeting 9 discusses medicinal cannabis licensing, SAS approval trends, industry collaboration, road safety and regulatory priorities.

AACMC Meeting 8 discusses medicinal cannabis licensing, SAS online portal uptake, product quality assurance and global regulatory trends.

Clarification of medicinal cannabis cultivation and manufacture requirements, including permit timing, supply pathways and licensing obligations.

Independent review of the Narcotic Drugs Act 1967 with recommendations to support innovation and improve medicinal cannabis regulation.

The TGA will be hosting public meetings in February 2019 in Sydney, Brisbane and Melbourne.

Correcting the record on the 5 December 2016 Australian Financial Review story.

AACMC Meeting 7 discusses medicinal cannabis access, the PELICAN epilepsy report, streamlined SAS approvals and international regulatory developments.

AACMC Meeting 6 discusses medicinal cannabis export reforms, streamlined approvals, clinical research and regulatory developments.

Consumers should be cautious of misleading claims about CBD and hemp oil products that may not be approved for import or use in Australia.

AACMC Meeting 5 discusses streamlining medicinal cannabis approvals, clinical research, data collection, patient safety and licensing reforms.

AACMC Meeting 4 highlights medicinal cannabis clinical guidance, Special Access Scheme prescribing pathways, patient access and research progress.

Overview of regulatory changes allowing the export of medicinal cannabis products from Australia and other reforms to the Narcotic Drugs Regulation 2016.

AACMC Meeting 3 discusses medicinal cannabis clinical guidance, evidence for key conditions, prescribing experiences and jurisdictional alignment.

Clarification on importing medicinal cannabis under SAS Category A, including ODC requirements, approval timeframes and available access pathways.

Results of consultation on exporting Australian-grown medicinal cannabis, including stakeholder feedback and next steps for government.

Office of Drug control is seeking feedback on the potential export of medicinal cannabis.

AACMC Meeting 2 discusses medicinal cannabis patient access, Special Access Schemes, jurisdictional approvals and clinical guidance development.

Imported medicinal cannabis products only, not domestically produced product, can now be supplied through Special Access Scheme Category A.

Unregistered medicinal cannabis products can now be prescribed under the Special Access Scheme Category A.

Update on medicinal cannabis licence approvals, including newly granted licences, permits issued and progress of Australia's industry.